The institutional investor owned 506,075 shares of the company’s stock after selling 329,125 shares during the period. Stempoint Capital LP owned approximately 0.31% of Dyne Therapeutics worth $9,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the 1st quarter worth $26,000. Finally, Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 15th. Read MoreReceive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.